A series of emails that illustrate the widespread, illegal, and fraudulent nature of a $1.6 billion (US) deal to transfer the production of cell-derived stem cells to China for use in DRC, South Africa, and elsewhere.

The emails were obtained by The Intercept and were shared with The Verge by a source with knowledge of the matter.

In the first email, dated December 4, 2017, Raytheon’s director of strategic initiatives, David Hwang, wrote that “we are moving the cells from the United States to China as soon as possible,” and that “this has been an ongoing effort and we are in the process of approving it.”

In response, RayTheon’s CEO, William Gorman, wrote, “It’s important to note that this process has not started yet and we have not announced a date for completion,” but the next steps will be “very soon.”

On December 8, 2017 , Raytheons senior vice president for R&D, Mike Lefevre, wrote to RayTheons general counsel, John M. Schmidhuber, to discuss a plan to transfer some of the cells that are currently being used in the US and to have some of those cells shipped to China.

“The cells are being processed at our labs in New Mexico and we want to send them to a company in China to be used in DSR [the stem cell therapy] trials,” he wrote.

“The reason is that they’re not used in clinical trials in the U.S. They’re going to be a great source of funding for this new research and we’re hoping to be able to do this in a relatively short period of time.”

Later in the same email, Schmidhuber wrote, “[the] US has been doing cell line transplants for a long time and have been successful.

The technology is not developed enough to be viable in a clinical trial, but we can help.

We have been working closely with our Chinese partner to get these cells to them.”

Raytheontomicrotechnologies, Inc., (Raytheon) “This is a massive investment,” Hwang wrote, adding, “we need to have it done as soon a possible.”

Two days later, on December 10, 2017 In another email, on the same day, Hwang writes, “Raytheons labs in Mexico are not ready to receive these cells.

We are still negotiating with them about a delivery date.”

“We’re not able to deliver these cells until we have a plan,” Lefvre wrote.

Raytheontoprops CEO, H.J. Pascual, wrote back, “Yes, we need to get the cells in to our labs ASAP.”

Schmidhubers response: “We will be working with Raytheo’s labs in the next 24 hours.”

RayTheon, RayTek, and others “have not been able to obtain approval for their stem cell production from the U,S.

FDA, which is the basis of our agreement with the company to move the cells to a new lab in China.

RayTheo has been very cooperative and cooperative in the discussions we’ve had with them and the US FDA.

We’re excited to have this agreement in place to move this project forward,” said Schmid-huber.

Despite the letter from Hwang and the agreement between RayTheontomrotechnologies and RayTheotek, Hange’s emails do not mention any mention of the deal in the emails shared with the news outlet.

A source familiar with the matter told The Intercept that there was “no mention of this deal in RayTheone emails, even though the companies knew about it for months.”

The Intercept reported in January that “RayTheo and RayTec” were involved in a “massive” scam that was “likely the biggest scam of its kind in history.”

The source said the scheme involved a Chinese company, called “Shaolong,” and two of RayTheoton’s Chinese partners, Raytec and ShaoTech, that were able to “buy” a small portion of a US company, RayTechnologies, which “had a patent on the cell-based technology that would allow them to mass produce cells.”

The scam involved “massive amounts of money, stolen data, and other things,” according to The Intercept.